Latysheva et al. [40] found no significant difference between the MGMT methylation group and the MGMT-unmethylated group in FA and MD parameters in enhancement regions of the tumour by analysing DTI quantitative parameters in 42 cases of GBM, which is also aligns with our results. The gene discussed is MGMT; the disease is glioblastoma.